F182112 not checked
Shandong New Time Pharmaceutical Co., LTD · BCMA CD3 · CD38 monoclonal antibody
FollowEvery change as it happens, and a Monday email
Trials
12 active
15 in total · 11 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)”In the company’s words, NCT07579234 on ClinicalTrials.gov
- Tested for
- Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed or Refractory Multiple Myeloma, Systemic Lupus Erythematosus (SLE)
- Main trialPhase 3
- “A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma”In the company’s words, NCT07579234 on ClinicalTrials.gov
- Other names
- Pomalidomide · BCMA CD3 · CD38 monoclonal antibody
Other drugs for Relapsed or Refractory Multiple Myeloma (RRMM)
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up3
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 20 May 2028Phase 2 trial completes · ClinicalTrials.gov
- 25 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 25 Jan 2029 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Recruiting | 20 May 2028 | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Recruiting | 31 Dec 2027 | F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus | |
| Phase 1Unknown | 30 Jul 2023 | Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Authorised | not given | Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO] | |
| Phase 1/2Authorised | not given | Pomalidomide as an immune-enhancing agent for the control of HIV (PEACH): An investigator-initiated phase I/IIb clinical trial in people living with HIV on ART and during analytical treatment interruption. | |
| Phase 2Ended | not given | A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy | |
| Phase 2Authorised | not given | Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study) | |
| Phase 2Authorised | not given | A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor | |
| Phase 1/2Authorised | not given | A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ONE TO THREE LINES OF THERAPY WHO ARE LENALIDOMIDE REFRACTORY | |
| Phase 2Ended | not given | ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma | |
| Phase 2Authorised | not given | A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma | |
| Phase 3Authorised | not given | A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) | |
| Phase 1/2Authorised | not given | Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study) | |
| Phase 2Authorised | not given | A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026